Premium
Sirolimus Enhances the Magnitude and Quality of Viral‐Specific CD8 + T‐Cell Responses to Vaccinia Virus Vaccination in Rhesus Macaques
Author(s) -
Turner A. P.,
Shaffer V. O.,
Araki K.,
Martens C.,
Turner P. L.,
Gangappa S.,
Ford M. L.,
Ahmed R.,
Kirk A. D.,
Larsen C. P.
Publication year - 2011
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2010.03407.x
Subject(s) - vaccinia , modified vaccinia ankara , sirolimus , immune system , cd8 , medicine , immunology , cytotoxic t cell , effector , virology , virus , vaccination , biology , in vitro , biochemistry , gene , recombinant dna
Sirolimus is a potent antiproliferative agent used clinically to prevent renal allograft rejection. However, little is known about the effects of maintenance immunosuppressive agents on the immune response to potentially protective vaccines. Here we show that sirolimus paradoxically increases the magnitude and quality of the CD8 + T‐cell response to vaccinia vaccination in nonhuman primates, fostering more robust recall responses compared to untreated and tacrolimus‐treated controls. Enhancement of both the central and effector memory compartments of the vaccinia‐specific CD8 + T‐cell response was observed. These data elucidate new mechanistic characteristics of sirolimus and suggest immune applications extending beyond its role as an immunosuppressant.